Example: Heart Attack

Search clinical trials for: Atazanavir

Total 240 results

NCT04468087

Not yet recruiting

Antiviral Agents Against COVID-19 Infection

Conditions: COVID-19
NCT04459286

Not yet recruiting

The Nitazoxanide Plus Atazanavir for COVID-19 Study

Conditions: Covid-19
NCT04452565

Recruiting

NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection

Conditions: Coronavirus Infection; Severe Acute Respiratory Infection; Severe Acute Respiratory Syndrome Coronavirus 2
NCT04385719

Not yet recruiting

Drug-drug Interactions Between Remdesivir and Commonly Used Antiretroviral Therapy

Conditions: Ebola; HIV/AIDS
NCT04311957

Not yet recruiting

Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults

Conditions: HIV-1-infection; Antiretroviral Therapy
NCT04263350

Not yet recruiting

A Study to Examine the Acceptable Taste and to Estimate the Amount of Atazanavir and Cobicistat in the Body When Taken as a Combination Product Versus When Taken as Separate Products at the Same Time

Conditions: Healthy Volunteers
NCT04184869

Recruiting

Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials

Conditions: Solid Tumor; Hematological Malignancies
NCT04121195

Not yet recruiting

Dose Escalation Study to Determine the Pharmacokinetics of Atazanavir Administered With RIfampicin to HIV Positive Adults on sEcond-line ART Regimen With Suppressed HIV-1 Viral Load

Conditions: HIV/AIDS; Tuberculosis
NCT04022967

Not yet recruiting

ANRS 12372 MODERATO Study

Conditions: HIV-1-infection
NCT04021290

Active, not recruiting

Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA)

Conditions: HIV Infections
NCT03923231

Recruiting

Pharmacokinetics of Atazanavir in Special Populations

Conditions: HIV/AIDS; Tuberculosis
NCT03708861

Withdrawn

Pharmacokinetics of Maraviroc and Boosted Atazanavir Dual Regimen in Stable HIV-infected Patients

Conditions: HIV Infection
NCT03631732

Active, not recruiting

Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants

Conditions: HIV-1 Infection
NCT03256422

Active, not recruiting

Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients

Conditions: HIV Infections
NCT03194165

Recruiting

Population Pharmacokinetics of Antiretroviral in Children

Conditions: Minor Patient Treated by One or More Antiretroviral and for Which a Blood Test Has Been Performed
NCT03019783

Completed

Atazanavir and Endothelial Function in Older HIV Patients

Conditions: HIV
NCT02951052

Active, not recruiting

Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults

Conditions: Infection, Human Immunodeficiency Virus; HIV Infections
NCT02697851

Terminated

Pharmacokinetic Effect of Evotaz/Microgynon Co-administration

Conditions: HIV
NCT02652624

Completed

Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women

Conditions: HIV-1 Infection
NCT02652793

Unknown status

Simplification From Tenofovir Plus Lamivudine or Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir Plus Lamivudine in Virologically-Suppressed-HIVInfected Adults With Osteopenia

Conditions: Human Immunodeficiency Virus
NCT02641444

Terminated

Antiretroviral Localization in Gut-Associated Lymphoid Tissue and Lower Female Genital Tract Tissue of HIV+ Subjects

Conditions: HIV
NCT02616783

Completed

Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years

Conditions: HIV-1 Infection
NCT02616029

Completed

Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I

Conditions: HIV-1 Infection
NCT02605954

Completed

Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults

Conditions: HIV-1 Infection
NCT02603107

Completed

Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults

Conditions: HIV-1 Infection
NCT02589158

Completed

SSAT067 PK of Atazanavir/Cobicistat and Darunavir/Cobicistat

Conditions: HIV
NCT02566707

Terminated

Pharmacokinetics of Atazanavir /Dolutegravir/Lamivudine Regimen as Maintenance Regimen

Conditions: HIV-1 Infection
NCT02565888

Completed

A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat

Conditions: Hepatitis C; HIV
NCT02556268

Completed

Interaction With HIV Antiretroviral Agents

Conditions: HIV-DDI
NCT02542852

Unknown status

A Study of a Nucleoside Sparing Regimen in HIV-1 Infected Patients With Detectable Viremia

Conditions: HIV-1 Infection
NCT02532673

Completed

Impact of Hyperbilirubinemia Among HIV Patients Treated With Atazanavir

Conditions: HIV/AIDS
NCT02513147

Completed

HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen

Conditions: HIV-1
NCT02473328

Completed

Study Evaluating the Efficacy of a Reduced Dose Atazanavir in HIV-1-infected Patients

Conditions: HIV-1 Infection
NCT02469246

Completed

Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC

Conditions: HIV-1 Infection
NCT02457494

Unknown status

Kidney Stone Risk Factors in Patients Infected With HIV

Conditions: Nephrolithiasis; HIV
NCT02442700

Completed

Effects of Pitavastatin on Lipid Profiles in HIV-infected Patients With Dyslipidemia and Receiving Atazanavir/Ritonavir

Conditions: HIV; Dyslipidemia
NCT02404259

Completed

PK TDF in Thai HIV-infected Children

Conditions: HIV
NCT02397096

Active, not recruiting

Safety and Efficacy of a Switch to MK-1439A in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024)

Conditions: HIV-1 Infection
NCT02386098

Terminated

Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults

Conditions: HIV Infections
NCT02307656

Unknown status

Taste Properties of Atazanavir and Cobicistat

Conditions: HIV in Adults
NCT02302547

Completed

Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy

Conditions: HIV
NCT02297126

Active, not recruiting

A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program

Conditions: Adverse Drug Reaction
NCT02285114

Active, not recruiting

Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected Children and Adolescents Virologically Suppressed on a 2-NRTI-Containing Regimen

Conditions: HIV-1
NCT02269917

Active, not recruiting

Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants

Conditions: Human Immunodeficiency Virus Type 1
NCT02257008

Completed

Effect of Different Boosting Agents on Pharmacokinetics of BILR 355 BS Dissolved in Polyethylene Glycol 400 (PEG 400) in Healthy Male Volunteers

Conditions: Healthy
NCT02253836

Completed

Pharmacokinetic Study in Healthy Adult Volunteers to Assess the Interactions Between Steady-State Tipranavir and Atazanavir in the Presence of Ritonavir

Conditions: Healthy
NCT02246998

Completed

Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults

Conditions: HIV-1 Infection
NCT02157311

Completed

4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV Patients

Conditions: HIV-1 Infection
NCT02155101

Completed

Efficacy and Safety Study of Darunavir for the Treatment of HIV/AIDS

Conditions: HIV/AIDS
NCT02154360

Completed

Pharmacokinetic Characteristics and Anti-Inflammatory Effects of Aprepitant In HIV-Infected Subjects

Conditions: HIV Infection

Search clinical trials for: Atazanavir

Recent CRA jobs

Global Supply Chain Specialist

Contract Associate / Analyst I - Grad Opportunity

Clinical Sample Processor - Monday-Friday 9:30a-6p

Principal Statistical Programmer (Remote)

Admin Asst Inter I

Technicien(ne)s de laboratoire

Account Director / Associate Director (Medical Education Communications)

Associate Sales Consultant (CMF) - Medical Device - Cleveland OH FYA01765

Digital Marketing Specialist

Cardiovascular Medical Science Liaison - West - 2671275